Biomodulatory metronomic therapy induces PET-negative remission in chemo- and brentuximab-refractory Hodgkin lymphoma.
Ugocsai, Peter
Biomodulatory metronomic therapy induces PET-negative remission in chemo- and brentuximab-refractory Hodgkin lymphoma. [electronic resource] - British journal of haematology Jan 2016 - 290-3 p. digital
Publication Type: Case Reports; Letter
1365-2141
10.1111/bjh.13480 doi
Adult
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Brentuximab Vedotin
Drug Administration Schedule
Female
Hodgkin Disease--drug therapy
Humans
Immunoconjugates--administration & dosage
Immunologic Factors--administration & dosage
Male
Positron-Emission Tomography
Remission Induction
Salvage Therapy--methods
Biomodulatory metronomic therapy induces PET-negative remission in chemo- and brentuximab-refractory Hodgkin lymphoma. [electronic resource] - British journal of haematology Jan 2016 - 290-3 p. digital
Publication Type: Case Reports; Letter
1365-2141
10.1111/bjh.13480 doi
Adult
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Brentuximab Vedotin
Drug Administration Schedule
Female
Hodgkin Disease--drug therapy
Humans
Immunoconjugates--administration & dosage
Immunologic Factors--administration & dosage
Male
Positron-Emission Tomography
Remission Induction
Salvage Therapy--methods